GPA project Location:HomeCPC MeetingGPA project

       Psoriasis is a chronic, inflammatory, recurrent and systemic disease, which is caused by genetic, environmental and immune factors. There are about 100 million psoriasis patients in the world. The prevalence of psoriasis varies in different regions. The prevalence rate is higher in Europe (2% - 5%), the United States (0.5% - 3%), and Asia (0.3% - 1%). Psoriasis has a great negative impact on the physiology and psychology of patients.

111.png

        In 2012, the International Federation of dermatological associations (ILDs) identified psoriasis as one of its "major challenges to global skin health". In 2014, the World Health Assembly decided that psoriasis is a serious non communicable disease. In 2016, the global report on psoriasis was published. The report pointed out that psoriasis seriously affects the life of patients in all aspects. High quality epidemiological data of psoriasis are essential for psoriasis control and proper health care planning. High quality data on incidence rate and prevalence of psoriasis can help us better understand the size and distribution of psoriasis. Most studies on the prevalence of disease are conducted in Europe and the United States. There are very few studies in Asia, Africa and South America, and few studies have focused on the incidence rate of psoriasis (new cases).


222.png

        Based on the above situation, the International Federation of psoriasis associations (IFPA), the International Federation of Dermatology associations (ILDs) and the international psoriasis Association (IPC) have taken the lead to promote the formation of global psoriasis Atlas (GPA).

333.png

444.png


        Atlas refers to the database of health information related to different geographical regions, including information on epidemiology, health care structure, process and results. "GPA" refers to the psoriasis information database in different regions of the world. The aim is to establish a credible and reliable database to record and use psoriatic health data from all over the world to identify the global burden of psoriasis, observe the incidence rate changes over time, and the economic burden of related complications to patients, so as to provide accurate health data for policymakers, stakeholders, health workers and patients all over the world. GPA is a long-term project, The purpose of GPA is to continuously improve the cognition of psoriasis and reveal how it affects individuals and the whole society. GPA is based on the scientific methods of epidemiology and health service research. In the first stage, GPA focuses on the prevalence and prevalence of psoriasis. In the future, it plans to increase the diagnosis and treatment of psoriasis, comorbidity, quality of life of patients and improvement of economic burden. GPA will become an important source of global psoriasis epidemiological resources, which will provide information for the research, policy and health care of psoriasis worldwide.

        GPA has monitoring sites on all five continents, and 17 GPA global coordinators have been developed. Professor Zhang Xuejun is one of them. He is not only responsible for China psoriasis surveillance project, but also responsible for providing opportunities for other people in the region to join the global project; recruiting and registering cooperation centers and identifying key investigators; distributing GPA learning materials and questionnaires; and cooperating with regional coordinators To participate in the implementation of GPA activities and projects; to organize international cooperation center meeting to discuss the results of GPA and actively transmit the survey results of the country.


555.png


        The international GPA project is composed of two working groups: Working Group 1 is responsible for the extensive and systematic review of the literature published in high impact journals and journals, and continuous literature retrieval to update the systematic review. A systematic review of the largest incidence rate and prevalence of psoriasis has been completed and a systematic review of the risk of cancer onset and mortality in psoriasis is completed. At present, a consensus on the diagnostic criteria of psoriasis in adults is being established to systematically review the economic impact of psoriasis.

        Working group 2 is responsible for developing a set of standard operating procedures for collecting epidemiological data of psoriasis around the world, conducting GPA online surveys and actively conducting epidemiological field surveys of psoriasis in various regions. We have completed the psoriasis health care survey in 16 countries in Latin America, and are preparing to publish the relevant results. At this stage, we are carrying out the psoriasis health questionnaire survey in Latin America, and are preparing the ethical application of psoriasis treatment survey research in Australia, Africa and Asia.


6-1.png     6-2.png


        As the director of GPA China, Professor Zhang Xuejun took the lead in establishing the China Committee of global psoriasis surveillance program (GPA) in October 2019. The first batch includes 100 GPa Chinese members and 100 GPa monitoring sites covering all provinces in China. Under the leadership of Professor Zhang Xuejun, China's GPA project plans to complete the establishment of China's GPA psoriasis research cohort in 10 years, update the prevalence of psoriasis in China, and add Chinese regional data to the global psoriasis database. The specific tasks are as follows:


7-1.png     7-2.png


The first phase task: to carry out the psoriasis medical and health care survey in the whole country. On the one hand, Chinese dermatologists can have a preliminary understanding of the GPA project; on the other hand, they will investigate the medical environment, diagnosis and treatment of psoriasis, and health care in China, so as to understand the understanding and mastery degree of each specialist on psoriasis.

Phase II tasks:

        (1) To carry out a nationwide epidemiological survey of psoriasis patients, establish a Chinese GPA psoriasis research cohort, and complete the GPA psoriasis epidemiological survey. Patients were recruited through psoriatic Congress, dandelion program and other activities, and patients were recruited through various GPA monitoring points to let patients understand the GPA project, and strive to bring psoriasis patients across the country into the research cohort, so as to facilitate the unified management and monitoring of psoriasis patients and follow-up investigation in the later stage.

        (2) GPA. The annual GPA tour is held throughout the country. To promote the GPA project, promote psoriasis guidelines, popularize psoriasis knowledge, let more doctors and patients understand GPA project, and actively participate in the project.

        Up to now, China's GPA program has completed the first phase of the survey. We have collected thousands of answers from dermatologists across the country to help us understand the overall medical environment of dermatology in China, the familiarity of dermatologists to psoriasis, the understanding of psoriasis guidelines, the understanding and use of biological agents and bio generics, etc., so as to formulate a unified diagnosis of psoriasis in the future The treatment standard and psoriasis cohort construction laid a solid foundation. Based on 260 psoriasis clinics and the first batch of GPA monitoring sites in China, it is planned to carry out epidemiological survey of psoriasis patients and GPA training tour in all provinces of China in 2020.

        Through the GPA project, we can understand the current incidence of psoriasis and its comorbidities in China, and understand the understanding of dermatologists in China on psoriasis and other related knowledge. GPA project plays an important role in promoting the clinical diagnosis and treatment level of psoriasis, improving the management level of psoriasis, establishing a National Psoriasis cohort study, long-term follow-up of patients, and effectively improving the quality of life of patients with psoriasis.


China Psoriasis Network CPC2020

Xu Xiangmei (Conference consultation)
Mobile:15005604686
Email:1225856963@qq.com
Zhu Xiaofeng (Registration consulting)
Mobile:15156991066
Email:307676249@qq.com

Copyright: China Psoriasis Network Wanicp Bei 11019793 皖公网安备 34019202000792号